An Australian study explored the predictive and prognostic ability of two PET imaging-based biomarkers to guide treatment with Novartis' radioligand therapy.
(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Novartis AG's therapy for the treatment of adult patients with a certain type .